Delgocitinib ointment, as a JAK inhibitor, is mainly used for the treatment of atopic dermatitis. Its mechanism of action and drug interactions require special attention. The following is a detailed explanation:

1. Effect of action

(1) By selectively inhibiting the JAK1/3 pathway, pro-inflammatory cytokine signaling is blocked.

(2) Clinical data shows that itching significantly improves within 2 weeks of medication, and the skin lesion regression rate reaches 60-70% within 4 weeks.

2 drug interactions

(1) Strong CYP3A4 inhibitors (such as ketoconazole): may increase the blood concentration of metformin, and adverse reactions need to be monitored.

(2) Immunosuppressants (such as cyclosporine): may increase the risk of infection, avoid combination use.

(3) Live vaccine: Vaccination during treatment may reduce vaccine efficacy, and it is recommended to have an interval of at least 4 weeks.

Attention to 3 special groups

(1) Patients with liver dysfunction: Moderate damage patients should reduce their dosage by 50%.

(2) Pregnancy period: Animals show embryotoxicity, human data is limited, and the pros and cons need to be weighed.

4. Use monitoring

(1) Regularly check blood routine and liver and kidney function during treatment.

(2) If severe infection symptoms occur, medication should be stopped immediately.

5 Precautions

(1) Skin monitoring: Irritation symptoms such as burning sensation and erythema may occur at the medication site, and if they continue to worsen, medication should be discontinued.

(2) Infection risk: JAK inhibitors may increase the probability of infection. If fever or skin suppuration occurs, medical attention should be sought.

(3) Contact transmission: Avoid contact between ointment and others' eye area or mucous membrane, wash hands after administration.

(4) Treatment limit: Continuous use should not exceed 4 weeks, and long-term use requires assessment of the risk of skin atrophy.

6 Special populations

(1) Children: Safety has not been established for children under 2 years old, and dosage should be strictly adjusted according to body weight for children aged 2-11.

(2) Elderly people are more prone to skin atrophy and need to shorten the treatment period and strengthen moisturizing care.

(3) Patients with liver injury: For those with moderate liver dysfunction, a 50% reduction is required, and severe use is prohibited.